Lung Cancer

Bevacizumab + Osimertinib Did Not Increase Progression-Free Survival versus Osimertinib Alone in Patients with Advanced Adenocarcinoma and EGFR T790M Mutations

Lung Cancer

2020 Year in Review: Non–Small-Cell Lung Cancer

Study results show no increase in progression-free survival with combination treatment of osimertinib and bevacizumab compared with osimertinib alone for patients with advanced lung adenocarcinoma and an EGFR T790M mutation.

Lower Dose of Afatinib Shows Promising Clinical Efficacy in Patients with NSCLC and EGFR Mutation

Lung Cancer

2020 Year in Review: Non–Small-Cell Lung Cancer

Patients treated with afatinib for EGFR-mutated (EGFRm) non–small-cell lung cancer (NSCLC) often require treatment modifications because of drug toxicities. This study aimed to evaluate the safety and efficacy of a lower dosage of afatinib in patients with EGFRm NSCLC.

Tepotinib in NSCLC with MET Exon 14 Skipping Mutation (VISION Study)

Lung Cancer

2020 Year in Review: Non–Small-Cell Lung Cancer

The open-label, phase 2 VISION study evaluated the efficacy and safety of tepotinib, a highly selective oral MET inhibitor, in patients with advanced NSCLC with MET alterations.

ADAURA Trial: Osimertinib in Resected EGFR-Mutated NSCLC

Lung Cancer

2020 Year in Review: Non–Small-Cell Lung Cancer

Osimertinib shows promise as an adjuvant treatment for patients with stage IB to IIIA EGFR mutation–positive NSCLC.

The Role of Rearrangement During Transfection (RET) Fusions as Oncogenic Drivers

Lung Cancer

Web Exclusives

Molecular Profiling Plays a Key Role in Optimizing NSCLC Therapy

Lung Cancer

Web Exclusives

Combination Cyramza and Tarceva Approved for First-Line Treatment of Metastatic NSCLC with EGFR Mutation

Lung Cancer